We acknowledge tumor genomic features can evolve throughout multiple lines of cancer treatment, so we subsequently limited our analysis to patients who received genetic testing within 2 years of starting 177Lu-PSMA-617, PSA50 responses were persistently lower in the AR alterations group. Here, FOLH1 is linked to neoplasm.